105 related articles for article (PubMed ID: 17008607)
1. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
Earnshaw SR; Joshi AV; Wilson MR; Rosand J
Stroke; 2006 Nov; 37(11):2751-8. PubMed ID: 17008607
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.
Kissela BM; Eckman MH
BMC Neurol; 2008 May; 8():17. PubMed ID: 18489750
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
5. Recombinant activated factor VII for acute intracerebral hemorrhage.
Mayer SA; Brun NC; Begtrup K; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
N Engl J Med; 2005 Feb; 352(8):777-85. PubMed ID: 15728810
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.
Mayer SA; Brun NC; Begtrup K; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
N Engl J Med; 2008 May; 358(20):2127-37. PubMed ID: 18480205
[TBL] [Abstract][Full Text] [Related]
7. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of transfers to centers with neurological intensive care units after intracerebral hemorrhage.
Fletcher JJ; Kotagal V; Mammoser A; Peterson M; Morgenstern LB; Burke JF
Stroke; 2015 Jan; 46(1):58-64. PubMed ID: 25477220
[TBL] [Abstract][Full Text] [Related]
9. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?
Mayer SA; Davis SM; Skolnick BE; Brun NC; Begtrup K; Broderick JP; Diringer MN; Steiner T;
Stroke; 2009 Mar; 40(3):833-40. PubMed ID: 19150875
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis.
Earnshaw SR; Jackson D; Farkouh R; Schwamm L
Stroke; 2009 May; 40(5):1710-20. PubMed ID: 19286581
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.
Ho KM; Litton E
Transfusion; 2012 Aug; 52(8):1696-702. PubMed ID: 22211634
[TBL] [Abstract][Full Text] [Related]
12. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.
Diringer MN; Skolnick BE; Mayer SA; Steiner T; Davis SM; Brun NC; Broderick JP
Stroke; 2008 Mar; 39(3):850-6. PubMed ID: 18239180
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever.
Naing C; Poovorawan Y; Mak JW; Aung K; Kamolratankul P
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):403-7. PubMed ID: 25692521
[TBL] [Abstract][Full Text] [Related]
14. Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials.
Gladstone DJ; Aviv RI; Demchuk AM; Hill MD; Thorpe KE; Khoury JC; Sucharew HJ; Al-Ajlan F; Butcher K; Dowlatshahi D; Gubitz G; De Masi S; Hall J; Gregg D; Mamdani M; Shamy M; Swartz RH; Del Campo CM; Cucchiara B; Panagos P; Goldstein JN; Carrozzella J; Jauch EC; Broderick JP; Flaherty ML;
JAMA Neurol; 2019 Dec; 76(12):1493-1501. PubMed ID: 31424491
[TBL] [Abstract][Full Text] [Related]
15. Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.
Diringer MN; Ferran JM; Broderick J; Davis S; Mayer SA; Steiner T; Brun NC; Skolnick BE; Christensen MC
Cerebrovasc Dis; 2007; 24(2-3):219-25. PubMed ID: 17630481
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial.
Mayer SA; Brun NC; Broderick J; Davis SM; Diringer MN; Skolnick BE; Steiner T;
Neurocrit Care; 2006; 4(3):206-14. PubMed ID: 16757825
[TBL] [Abstract][Full Text] [Related]
17. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
Mayer SA; Brun NC; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
Stroke; 2005 Jan; 36(1):74-9. PubMed ID: 15569871
[TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Selin S; Tejani A
Issues Emerg Health Technol; 2006 Mar; (82):1-4. PubMed ID: 16602203
[TBL] [Abstract][Full Text] [Related]
19. Intracerebral hemorrhage: outcomes and eligibility for factor VIIa treatment in a National Stroke Registry.
Nadeau JO; Phillips S; Shi HS; Kapral MK; Gladstone DJ; Silver FL; Hill MD;
Cerebrovasc Dis; 2006; 22(4):271-5. PubMed ID: 16788301
[TBL] [Abstract][Full Text] [Related]
20. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
Hay JW; Chaugule SC; Young G
Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
